Colon cancer

Critical Reviews in Oncology/Hematology

Volumn 74, Issue 2, 2010, Pages 106-133

  Labianca, Roberto ^a   Beretta, Giordano D ^b   Kildani, Basem ^b   Milesi, Laura ^a   Merlin, Federica ^b   Mosconi, Stefania ^a   Pessi, M Adelaide ^a   Prochilo, Tiziana ^b   Quadri, Antonello ^a   Gatta, Gemma ^c   de Braud, Filippo ^d   Wils, Jacques ^e  

^a OSPEDALI RIUNITI   (Italy)

^b S Orsola Hospital   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e LAURENTIUS HOSPITAL   (Netherlands)

Author keywords

Colon cancer; Strategy; Treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; UFT;

ADD ON THERAPY; ALLERGIC REACTION; ALOPECIA; BILIARY TRACT DISEASE; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LIVER FUNCTION TEST; LIVER METASTASIS; LOW DRUG DOSE; LUNG CANCER; LUNG METASTASIS; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PROFESSIONAL PRACTICE; PROSTATE CANCER; PROTEINURIA; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOSIS; VOMITING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COLONIC NEOPLASMS; HUMANS; INCIDENCE; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 77950085360     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.01.010     Document Type: Review

References (225)

1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Lyon: International Agency for Research on Cancer. Vol. VIII. IARC Scient. Publ. No. 155. 2002.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARC Press; 2004.
3. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37(Suppl. 8):S4-S66.
4. Grande E., Inghelmann R., Francisci S., et al. Regional estimates of colorectal cancer burden in Italy. Tumori 2007, 93:352-359.
5. Berrino F., De A.R., Sant M., et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol 2007, 8:773-783.
6. Coleman M.P., Gatta G., Verdecchia A., et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003, 14(Suppl. 5):v128-v149.
7. Engholm G., Kejs A.M., Brewster D.H., et al. Colorectal cancer survival in the Nordic countries and the United Kingdom: excess mortality risk analysis of 5 year relative period survival in the period 1999 to 2000. Int J Cancer 2007, 121:1115-1122.
8. Verdecchia A., Francisci S., Brenner H., et al. Recent cancer survival in Europe: a 2000-2002 period analysis of EUROCARE-4 data. Lancet Oncol 2007, 8:784-796.
9. Kwak E.L., Chung D.C. Hereditary colorectal cancer syndromes: an overview. Clin Colorectal Cancer 2007, 6:340-344.
10. Tomatis L. Cancer, causes, occurrence and control. Lyon: IARC Press. Pubbl. no. 100; 1990.
11. WCRF& AICR. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
12. World cancer report 2003, IARC Press, Lyon. B.W. Stewart, P. Kleihus (Eds.).
13. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001, 10:725-731.
14. Asano T.K., McLeod R.S. Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum 2004, 47:665-673.
15. von Roon A.C., Reese G., Teare J., et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 2007, 50:839-855.
16. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
17. Cali R.L., Pitsch R.M., Thorson A.G., et al. Cumulative incidence of metachronous colorectal cancer. Dis Colon Rectum 1993, 36:388-393.
18. Ahmed R.L., Schmitz K.H., Anderson K.E., Rosamond W.D., Folsom A.R. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006, 107:28-36.
19. Chlebowski R.T., Wactawski-Wende J., Ritenbaugh C., et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004, 350:991-1004.
20. Aarnio M., Sankila R., Pukkala E., et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81:214-218.
21. Cochrane. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001216 Screening for colorectal cancer using the faecal occult blood test, Hemoccult; 2007.
22. Hakama M., Coleman M.P., Alexe D.M., Auvinen A. Cancer screening: evidence and practice in Europe 2008. Eur J Cancer 2008, 44:1404-1413.
23. Advisory Committee on Cancer Prevention (ACCP) Recommendations on cancer screening in the European union. Eur J Cancer 2000, 36:1473-1478.
24. Winawer S., Fletcher R., Rex D., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003, 124:544-560.
25. Bodmer W.F., Bailey C.J., Bodmer J., et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987, 328:614-616.
26. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-532.
27. Forrester K., Almoguera C., Han K., Grizzle W.E., Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987, 327:298-303.
28. Kinzler K.W., Nilbert M.C., Vogelstein B., et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 1991, 251:1366-1370.
29. Broders A.C. The grading of carcinoma. Minn Med 1925, 8:726-730.
30. Dukes C.E. The classification of cancer of the rectum. J Pathol 1932, 35:323-332.
31. Qizilbash A.H. Pathologic studies in colorectal cancer. A guide to the surgical pathology examination of colorectal specimens and review of features of prognostic significance. Pathol Annu 1982, 17:1-46.
32. Jass J.R., Atkin W.S., Cuzick J., et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986, 10:437-459.
33. Vining D.J., Gelfand D.W., Bechtold R.E. Technical feasibility of colon imaging with helical CT and virtual reality. AJR Am J Roentgenol 1994, 162(Suppl.):104.
34. Pickhardt P.J., Choi J.R., Hwang I., et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003, 349:2191-2200.
35. Cotton P.B., Durkalski V.L., Pineau B.C., et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 2004, 291:1713-1719.
36. Luboldt W., Bauerfeind P., Wildermuth S., et al. Colonic masses: detection with MR colonography. Radiology 2000, 216:383-388.
37. Hartmann D., Bassler B., Schilling D., et al. Colorectal polyps: detection with dark-lumen MR colonography versus conventional colonoscopy. Radiology 2006, 238:143-149.
38. Leung W.K., Lam W.W., Wu J.C., et al. Magnetic resonance colonography in the detection of colonic neoplasm in high-risk and average-risk individuals. Am J Gastroenterol 2004, 99:102-108.
39. Bresalier R.A., Boland C.R., Itzkowitz S.H., Kim Y.S. Basic gastrointestinal oncology. The gastroeneterology annual 1989, vol. 2:271-319. Elsevier/North Holland, Amsterdam.
40. Fletcher R.H. Carcinoembryonic antigen. Ann Intern Med 1986, 104:66-73.
41. Cohen A.M., Minsky B.D., Schilsky R.L. Colon cancer. Cancer: principles and practice of oncology 1993, 929-977. JB Lippincott Company, Philadelphia. 4th ed. V.T. De Vita, S. Hellman, S.A. Rosenberg (Eds.).
42. Eisenberg B., DeCosse J.J., Harford F., Michalek J. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer 1982, 49:1131-1134.
43. Newland R.C., Chapuis P.H., Pheils M.T., MacPherson J.G. The relationship of survival to staging and grading of colorectal carcinoma: a prospective study of 503 cases. Cancer 1981, 47:1424-1429.
44. Olson R.M., Perencevich N.P., Malcolm A.W., Chaffey J.T., Wilson R.E. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer 1980, 45:2969-2974.
45. Zinkin L.D. A critical review of the classifications and staging of colorectal cancer. Dis Colon Rectum 1983, 26:37-43.
46. UICC (International Union Against Cancer). TNM classification of malignant tumours, 6th ed. Sobin LH, Wittekind Ch, editors. New York, Chichester, weinheim, Brisbane, Singapore, Toronto: Wiley-Liss. 2002.
47. Dershaw D.D., Enker W.E., Cohen A.M., Sigurdson E.R. Transrectal ultrasonography of rectal carcinoma. Cancer 1990, 66:2336-2340.
48. Butch R.J., Stark D.D., Wittenberg J., et al. Staging rectal cancer by MR and CT. AJR Am J Roentgenol 1986, 146:1155-1160.
49. Guinet C., Buy J.N., Ghossain M.A., et al. Comparison of magnetic resonance imaging and computed tomography in the preoperative staging of rectal cancer. Arch Surg 1990, 125:385-388.
50. Van Cutsem E., Dicato M., Wils J., et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer 2002, 38:1429-1436.
51. Compton C.C. The pathology report in colorectal cancer: a user's guide. ASCO Educ 2003, 502-516.
52. Tepper J.E., O'Connell M.J., Niedzwiecki D., et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001, 19:157-163.
53. Holscher A.H. Invasive ultrasound: value of intraoperative and laparoscopic ultrasound imaging. Bildgebung 1995, 62(Suppl. 1):39-42.
54. Steinberg S.M., Barkin J.S., Kaplan R.S., Stablein D.M. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 1986, 57:1866-1870.
55. Sternberg A., Sibirsky O., Cohen D., Blumenson L.E., Petrelli N.J. Validation of a new classification system for curatively resected colorectal adenocarcinoma. Cancer 1999, 86:782-792.
56. Deans G.T., Parks T.G., Rowlands B.J., Spence R.A. Prognostic factors in colorectal cancer. Br J Surg 1992, 79:608-613.
57. Arbman G., Nilsson E., Hallbook O., Sjodahl R. Local recurrence following total mesorectal excision for rectal cancer. Br J Surg 1996, 83:375-379.
58. Wolmark N., Wieand H.S., Rockette H.E., et al. The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg 1983, 198:743-752.
59. Filella X., Molina R., Grau J.J., et al. Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg 1992, 216:55-59.
60. Fitzgerald S.D., Longo W.E., Daniel G.L., Vernava A.M. Advanced colorectal neoplasia in the high-risk elderly patient: is surgical resection justified?. Dis Colon Rectum 1993, 36:161-166.
61. Stephenson K.R., Steinberg S.M., Hughes K.S., et al. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg 1988, 208:679-687.
62. Voogt P.J., van d V., Brand A., et al. Perioperative blood transfusion and cancer prognosis. Different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer 1987, 59:836-843.
63. Heiss M.M., Mempel W., Delanoff C., et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994, 12:1859-1867.
64. Busch O.R., Hop W.C., Hoynck vPM, Marquet R.L., Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993, 328:1372-1376.
65. Donohue J.H., Williams S., Cha S., et al. Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study. J Clin Oncol 1995, 13:1671-1678.
66. Kohne C.H., Cunningham D., Di C.F., et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002, 13:308-317.
67. Sargent D.J., Kohne C.H., Sanoff H.K., et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 2009, 27:1948-1955.
68. Buyse M., Thirion P., Carlson R.W., et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000, 356:373-378.
69. Douillard J.Y., Bennouna J. Adjuvant chemotherapy for colon cancer: a confusing area!. Ann Oncol 2005, 16:1853-1854.
70. Wils J. Adjuvant treatment of colon cancer: past, present and future. J Chemother 2007, 19:115-122.
71. Wang Y., Jatkoe T., Zhang Y., et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004, 22:1564-1571.
72. Weiser M.R., Landmann R.G., Kattan M.W., et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol 2008, 26:380-385.
73. Chiara S., Nobile M.T., Vincenti M., et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998, 42:336-340.
74. NGTATG Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992, 10:904-911.
75. Scheithauer W., Rosen H., Kornek G.V., Sebesta C., Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993, 306:752-755.
76. Goldberg R.M., Hatfield A.K., Kahn M., et al. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 1997, 15:3320-3329.
77. Dwight R.W., Higgins G.A., Keehn R.J. Factors influencing survival after resection in cancer of the colon and rectum. Am J Surg 1969, 117:512-522.
78. Grinnell R.S. Results of ligation of the inferior mesenteric artery at the aorta in resections for carcinomas of the descending and sigmoid colon and rectum. Surg Gynecol Obstet 1965, 120:1031-1035.
79. O'Connell M.J., Mailliard J.A., Kahn M.J., et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15:246-250.
80. Haller DG, Eastern Cooperative Oncology Group. NCI High Priority Clinical Trial-Phase III Randomized Comparison of Adjuvant Low-Dose CF/5-FU vs High-Dose CF/5-FU vs Low-Dose CF/5-FU/LEV vs 5-FU/LEV Following Curative Resection in Selected Patients with Dukes' B2 and C Carcinoma of the Colon (Summary Last Modified 06/97), EST-2288, clinical trial, closed, 07/13/1992. TRIAL 1992;0.
81. Saini S., Cunningham D., Norman A., et al. Multicentre Randomized Trial OF Protracted Venous Infusion (PVI) 5FU compared to 5FU/folinic acid (5FU/FA) as adjuvant therapy for colorectal cancer. Proc ASCO 2000, 19:240a.
82. Andre T., Colin P., Louvet C., et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003, 21:2896-2903.
83. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
84. Andre T., Boni C., Navarro M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116.
85. Kuebler J.P., Wieand H.S., O'Connell M.J., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198-2204.
86. Allegra C.J., Yothers G., O'Connell M.J., et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009, 27:3385-3390.
87. Wolmark N., Yothers G., O'Connell M.J., et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol 2009, 27(18S):LBA4.
88. Cassidy J., Scheithauer W., McKendric J., et al. Capecitabine (X) versus bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (X-ACT study): positive efficacy results of a phase III trial. J Clin Oncol 2004, 22(14S):247s.
89. Twelves C., Wong A., Nowacki M.P., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
90. Schmoll H.J., Cartwright T., Tabernero J., et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients. J Clin Oncol 2007, 25:102-109.
91. Wolmark N., Wieand S., Lembersky B., et al. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. J Clin Oncol 2004, 22(14S).
92. Saltz L., Niedzwiecki D., Hollis D., et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc ASCO 2004, 22(14S):245s.
93. Van C.E., Labianca R., Bodoky G., et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009, 27:3117-3125.
94. Adam R. The importance of visceral metastasectomy in colorectal cancer. Ann Oncol 2000, 11(Suppl. 3):29-36.
95. Adson M.A., van Heerden J.A., Adson M.H., Wagner J.S., Ilstrup D.M. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984, 119:647-651.
96. Coppa G.F., Eng K., Ranson J.H., Gouge T.H., Localio S.A. Hepatic resection for metastatic colon and rectal cancer. An evaluation of preoperative and postoperative factors. Ann Surg 1985, 202:203-208.
97. Scheele J., Stangl R., Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990, 77:1241-1246.
98. Scheele J., Stangl R., Altendorf-Hofmann A., Gall F.P. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991, 110:13-29.
99. Wagman L.D., Kemeny M.M., Leong L., et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990, 8:1885-1893.
100. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
101. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
102. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18:136-147.
103. Goldberg R.M., Morton R.F., Sargent D.J., et al. N9741:oxaliplatin (oxal) or CPT-11+5-fluorouracil (5FU)/leucovorin (LV) or oxal+CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc ASCO 2002, 21:128a.
104. Grothey A., Deschler B., Kroening H., et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA+oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc ASCO 2002, 21:129a.
105. Kohne C.H., Van Cutsem E., Wils J., et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986. Proc ASCO 2003, 22:254.
106. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
107. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
108. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
109. Scheer M.G., Sloots C.E., van der Wilt G.J., Ruers T.J. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 2008, 19:1829-1835.
110. Daly J., Kemeny M. Therapy of colorectal hepatic metastases. Important advances in oncology 1986, 251-268. JB Lippincott Company, Philadelphia. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
111. Ridge J.A., Daly J.M. Treatment of colorectal hepatic metastases. Surg Gynecol Obstet 1985, 161:597-607.
112. Butler J., Attiyeh F.F., Daly J.M. Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet 1986, 162:109-113.
113. Ekberg H., Tranberg K.G., Andersson R., et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986, 73:727-731.
114. Wagner J.S., Adson M.A., van Heerden J.A., Adson M.H., Ilstrup D.M. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984, 199:502-508.
115. Barbare J.C., Bedenne L., Bouche O., et al. What can be done for patients with digestive cancer in 1999? Guidelines of the French Foundation of Digestive Cancerology (2nd part). Gastroenterol Clin Biol 1999, 23:486-496.
116. Hamady Z.Z., Cameron I.C., Wyatt J., et al. Resection margin in patients undergoing hepatectomy for colorectal liver metastasis: a critical appraisal of the 1cm rule. Eur J Surg Oncol 2006, 32:557-563.
117. Poston G.J., Adam R., Alberts S., et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005, 23:7125-7134.
118. Charnsangavej C., Clary B., Fong Y., et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006, 13:1261-1268.
119. Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001, 8:347-353.
120. Adam R., Pascal G., Azoulay D., et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003, 238:871-883.
121. Fortner J.G., Silva J.S., Golbey R.B., Cox E.B., Maclean B.J. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 1984, 199:306-316.
122. Adam R., Bismuth H., Castaing D., et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997, 225:51-60.
123. Nordlinger B., Vaillant J.C., Guiguet M., et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994, 12:1491-1496.
124. Petrowsky H., Gonen M., Jarnagin W., et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002, 235:863-871.
125. Morise Z., Sugioka A., Fujita J., et al. Does repeated surgery improve the prognosis of colorectal liver metastases?. J Gastrointest Surg 2006, 10:6-11.
126. Alberts S.R., Donohue J.H., Mahoney M.R., et al. Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study. Proc ASCO 2003, 22:263.
127. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999, 10:663-669.
128. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
129. Pozzo C., Basso M., Cassano A., et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004, 15:933-939.
130. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25:1670-1676.
131. Quenet F., Nordlinger B., Rivoire M., et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): a prospective phase II trial. Proc ASCO 2004, 22:273.
132. Folprecht G., Grothey A., Alberts S., Raab H.R., Kohne C.H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005, 16:1311-1319.
133. Kesmodel S.B., Ellis L.M., Lin E., et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008, 26:5254-5260.
134. Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008, 26:1830-1835.
135. Reddy S.K., Morse M.A., Hurwitz H.I., et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008, 206:96-106.
136. Langer B., Bleiberg H., Labianca R., et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc ASCO 2002, 21:149a.
137. Portier G., Elias D., Bouche O., et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006, 24:4976-4982.
138. Mitry E., Fields A.L., Bleiberg H., et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008, 26:4906-4911.
139. Mocellin S., Pilati P., Lise M., Nitti D. Hepatic arterial infusion (HAI) compared to systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma: a systematic review and meta-analysis of randomized controlled trials. J Clin Oncol 2007, 25(No. 18S):626s.
140. Kemeny N., Huang Y., Cohen A.M., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039-2048.
141. Kemeny N.E., Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005, 352:734-735.
142. Chang A.E., Schneider P.D., Sugarbaker P.H., et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987, 206:685-693.
143. Kemeny N., Daly J., Reichman B., et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987, 107:459-465.
144. Rougier P., Laplanche A., Huguier M., et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992, 10:1112-1118.
145. Kemeny N., Cohen A., Seiter K., et al. Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 1993, 11:330-335.
146. MAGC Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996, 88:252-258.
147. Dawson L.A., McGinn C.J., Normolle D., et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000, 18:2210-2218.
148. Ben Josef E., Normolle D., Ensminger W.D., et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005, 23:8739-8747.
149. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016.
150. Thomas D.S., Nauta R.J., Rodgers J.E., et al. Intraoperative high-dose rate interstitial irradiation of hepatic metastases from colorectal carcinoma. Results of a phase I-II trial. Cancer 1993, 71:1977-1981.
151. Berber E., Pelley R., Siperstein A.E. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005, 23:1358-1364.
152. McKay A., Dixon E., Taylor M. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg 2006, 93:1192-1201.
153. Al-Asfoor A., Fedorowicz Z., Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane Database Syst Rev 2008, CD006039.
154. Girard P., Ducreux M., Baldeyrou P., et al. Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol 1996, 14:2047-2053.
155. McAfee M.K., Allen M.S., Trastek V.F., et al. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992, 53:780-785.
156. Okumura S., Kondo H., Tsuboi M., et al. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 1996, 112:867-874.
157. Pfannschmidt J., Muley T., Hoffmann H., Dienemann H. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg 2003, 126:732-739.
158. Saito Y., Omiya H., Kohno K., et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002, 124:1007-1013.
159. Vogelsang H., Haas S., Hierholzer C., et al. Factors influencing survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004, 91:1066-1071.
160. Schmoll H., Kohne C.H., Lorenz M., et al. Weekly 24h infusion of high-dose (HD) 5-fluorouracil (5-FU24h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): a randomized phase III study of the EORTC GITCCG and the AIO. Proc ASCO 2000, 19:241a.
161. Cassidy J., Twelves C., Van Cutsem E., et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002, 13:566-575.
162. Hoff P.M., Royce M., Medgyesy D., Brito R., Pazdur R. Oral fluoropoyrimidines. Semin Oncol 1999, 26:640-646.
163. Saif M.W. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer 2005, 5:89-100.
164. Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 2002, 38(Suppl. 2):15-20.
165. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-914.
166. Saltz L.B., Douillard J., Pirrotta N., et al. Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC). Proc ASCO 2000, 19:242a.
167. Kohne C.H., Van Cutsem E., Wils J., et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005, 23:4856-4865.
168. Andre T., Bensmaine M.A., Louvet C., et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999, 17:3560-3568.
169. Bleiberg H., de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998, 25:32-39.
170. Cvitkovic E., Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 1999, 26:647-662.
171. de Gramont A., Vignoud J., Tournigand C., et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997, 33:214-219.
172. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23-30.
173. Sanoff H.K., Sargent D.J., Campbell M.E., et al. N9741: survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC). J Clin Oncol 2007, 25(No. 18S):180s.
174. Sargent D.J., Niedzwiecki D., O'Connell M.J., Schilsky R.L. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001, 345:144-145.
175. Rothenberg M.L., Meropol N.J., Poplin E.A., Van Cutsem E., Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001, 19:3801-3807.
176. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005, 23:4866-4875.
177. Grothey A., Sargent D., Goldberg R.M., Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004, 22:1209-1214.
178. Grothey A., Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005, 23:9441-9442.
179. Seymour M.T. Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer (ACRC). Proc ASCO 2005, 23(No. 16S):250s.
180. Punt C.J., Koopman M., Douma J., et al. Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study. Proc ASCO 2007, 25.
181. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006, 24:394-400.
182. Maindrault-Goebel F., Lledo G., Chibaudel B., et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. Proc ASCO 2007, 25(No. 18S):166s.
183. Labianca R., Floriani I., Cortesi E., et al. Alternating versus continuous " FOLFIRI" in advanced colorectal cancer (ACC): a randomized " GISCAD" trial. Proc ASCO 2006, 24(No. 18S):147s.
184. Massuti B., Gómez A., Sastre J., et al. Randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continuous infusion (FUFOX) as first line treatment in advanced or metastatic colorectal cancer (CRC). Proc ASCO 2006, 24(No. 18S):165s.
185. Arkenau H., Schmoll H., Kubicka S., et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): results of the safety and efficacy analysis. Proc ASCO 2005, 23(No. 16S):247s.
186. Cassidy J., Clarke S., Diaz-Rubio E., et al. XELOX compared to FOLFOX4: survival and response results from XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC). Proc ASCO 2007, 25(No. 18S):171s.
187. Rea D.W., Nortier J.W., Bokkel Huinink W.W., et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 2005, 16:1123-1132.
188. Fuchs C., Marshall J., Mitchell E., et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: updated efficacy data. Proc ASCO 2007, 25(No. 18S):170s.
189. Aust D., Kohne C., Goekkurt E., et al. Preliminary pharmacogenetic evaluation of toxicity data in the prospective multicentre EORTC trial 40015 in metastatic colorectal cancer (CRC). Proc ASCO 2006, 24(No. 18S):138s.
190. Allen-Mersh T.G., Earlam S., Fordy C., Abrams K., Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994, 344:1255-1260.
191. Glimelius B., Hoffman K., Graf W., Pahlman L., Sjoden P.O. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 1994, 73:556-562.
192. Eng C., Maurel J., Scheithauer W., et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. Proc ASCO 2007, 25(No. 18S):164s.
193. Au H., Karapetis C., Jonker D., et al. Quality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trial. Proc ASCO 2007, 25(No. 18S):164s.
194. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
195. Saltz L., Clarke S., Diaz-Rubio E., et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Proc ASCO 2007, 25.
196. Hochster H.S., Hart L.L., Ramanathan R.K., et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. Proc ASCO 2006, 24(No. 18S):148s.
197. Saltz L.B., Meropol N.J., Loehrer P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
198. Lenz H.J., Mayer R.J., Gold P.J., et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc ASCO 2004, 22:248.
199. Folprecht G., Cunningham D., Ross P., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004, 15:1330-1338.
200. Hohler T., Dittrich C., Lordick F., et al. A phaseI/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR): preliminary results. Ann Oncol 2004, 15(Suppl. 3):iii69.
201. Rosenberg A.H., Loehrer P.J., Needle M.N., et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc ASCO 2002, 21:135a.
202. Rougier P., Raoul J.L., Van Laethem J.L., et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc ASCO 2004, 22:248.
203. Van Cutsem E., Mayer R.J., Gold P., et al. Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur J Cancer 2004, 8(Suppl. 2):85-86. 279a.
204. Bokemeyer C., Bondarenko I., Makhson A., et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 2007, 25(No. 18S):172s.
205. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
206. Hecht J.R., Patnaik A., Malik I., et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc ASCO 2004, 22:248.
207. Van Cutsem E., Nowacki M., Lang I., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Proc ASCO 2007, 25.
208. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
209. Scartozzi M., Bearzi I., Berardi R., et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004, 22:4772-4778.
210. Van Cutsem E., Tabernero J., Diaz-Rubio E., et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Ann Oncol 2004, 15(Suppl. 3):iii91.
211. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23:1803-1810.
212. Lievre A., Bachet J.B., Le C.D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
213. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
214. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
215. Van Cutsem E., Lang I., D'haens G., et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008, 26(20 Suppl.):5s.
216. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008, 26(No. 15S):178s.
217. Di N.F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
218. Saltz L.B., Lenz H., Hochster H., et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO 2005, 23.
219. Punt C.J., Tol J., Rodenburg C.J., et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008, 26(Suppl.):180s.
220. Hecht J.R., Mitchell E., Chidiac T. An updated analysis of the safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev)±panitumumab (pmab) for firstline treatment (tx) of etastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Program and abstracts of the 2008 gastrointestinal cancers symposium 2008, abstract 2008.
221. Taylor I. Colorectal cancer-future trends. Eur J Surg Oncol 1995, 21:351-352.
222. Martin E.W.J., Minton J.P., Carey L.C. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg 1985, 202:310-317.
223. Moertel C.G., Fleming T.R., Macdonald J.S., et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993, 270:943-947.
224. Safi F., Link K.H., Beger H.G. Is follow-up of colorectal cancer patients worthwhile?. Dis Colon Rectum 1993, 36:636-643.
225. Bruinvels D.J., Stiggelbout A.M., Kievit J., et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994, 219:174-182.